Release and insufficient removal of endogenous nucleic acids may be involved in triggering autoimmune reactions important in the initiation of systemic autoimmune diseases including rheumatoid arthritis (RA). Nucleic acid sensing molecules, such as the endosomal Toll-like receptors (TLRs) 7 and 9, have been linked to pathogenic autoimmune processes, but their role in RA is less clear. To gain more insight into the role of TLR9 in autoimmune arthritis, TLR9 inhibition was investigated in rats with pristane-induced arthritis (PIA). To further investigate TLR9 involvement, serum transfer arthritis was induced in TLR9 knock-out mice. Materials and Methods: Arthritis was induced in mice with arthritogenic K/BxN serum and in rats with the mineral oil pristane. Rats were treated with a TLR9 antagonist, starting before disease induction. Arthritis was scored using established scoring systems, inflammation and bone erosion were quantified by histological analysis. The role of TLR9 in osteoclast differentiation and activation was investigated in vitro. Results: In the serum transfer model, which is independent of the adaptive immune system, arthritis severity was not changed in mice lacking a functional tlr9 gene. In PIA, which is T cell-dependent, the TLR9 antagonist reduced arthritis severity by ~50%. TLR9 inhibition led to reduced inflammation, bone erosion and cartilage degradation. However, when treatment was started after the onset of arthritis TLR9 inhibition did not influence disease severity. Treatment with the TLR9 antagonist influenced downstream signaling, mainly via NFκBp65, in lymph nodes. Remarkably, mRNA levels of TLR7 and TLR9 strongly differed in the course of in vitro osteoclastogenesis. Whereas TLR7 expression did not change throughout osteoclastogenesis, expression of TLR9 was higher in precursor cells than in mature osteoclasts and stimulation with a TLR9 agonist (CpG) completely inhibited osteoclastogenesis. Conclusions: Taken together, the results suggest a role for TLR9 in the T cell-dependent initiation phase of PIA and thus an important involvement of the DNA (CpG) recognizing TLR9 in the initiation of autoimmune arthritis and during osteoclastogenesis. The precise role(s) of TLR9 in the different stages of arthritis needs to be further elucidated in future experiments.
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MiR-146a a key player in bone metabolism
Aim: In recent years is has been shown, that depletion of B cells by administration of the chimeric anti-CD20 antibody Rituximab is a successful treatment of rheumatoid arthritis (RA). It is known that the efficacy of Rituximab is not directly linked to a reduction of circulating autoantibodies since there is no expression of CD20 on plasma B cells. Rituximab was also shown to be a potent drug for T-cell mediated diseases like multiple ies/ng DNA vs. 235 copies/ng DNA, p = 0.0001). To test for an increased proliferative history in the naïve subset we performed telomere length as well as telomerase activity analysis. A decrease in telomere length correlated with increasing age in HC (rs = −0.377, p = 0.007). This correlation could not be observed in pSS patients. Instead, patients already displayed significantly shortened telomeres at young age compared to age-matched HC (6.5 kbp vs. 7.0 kbp, p = 0.04). Moreover, the increase in age and the shortening of telomeres resulted in an elevation of telomerase activity in HC (rs = 0,579; p < 0.0001 and rs = −0.532; p < 0.0001), a finding that we could not observe in pSS patients. Conclusion: Our data indicate an extensive replicative history of naïve CD4+ T-cells in pSS already at young age, resulting in premature shortening of telomeres. In contrast to HC, naïve CD4+ T-cells from pSS patients are unable to induce telomerase activity. This telomerase deficiency may finally lead to the reduction of the naïve CD4+ T-cell pool resulting in CD4+ T-cell lymphopenia. Aim: Autoreactive T cells drive the inflammatory process, which leads to an irreversible destruction of the joints. Gene transcription and regulation of proinflammatory cytokine production in T cells is regulated by epigenetic mechanisms. Among them histone deacetylases (HDACs) modify the epigenetic landscape by removing acetyl groups of lysine residues of histones, resulting in chromatin condensation and repression of transcription. The application of pan-HDAC inhibitors has been shown to be a potential therapeutic strategy. However, major side effects limited the clinical use and underline the need of more specific HDAC inhibitors. Therefore we addressed the effects of selective HDACs on the development of autoimmune diseases. Methods: Mice with a T cell specific deletion of HDAC1 (HDAC1cKO) were generated by using the CD4Cre/LoxP system. The clinical and the histological phenotype were assessed in the collagen-induced arthritis (CIA) and the experimental autoimmune encephalitis (EAE) model. Anti-collagen antibody levels were determined by ELISA. Qualitative and quantitative analysis of T cell subsets of the spleen and draining LN were assessed using flow cytometry. Additionally comparative RNA-sequencing of CD4+ T cells from wild type (WT) and HDAC1cKO mice was performed. Results: To address whether HDAC1 is involved in the pathogenesis of autoimmune diseases we induced the CIA and the EAE in WT and HDAC1cKO mice. Surprisingly, despite the presence of serum anti-CII antibodies, HDAC1cKO mice did not develop any clinical or histological signs of inflammation in the CIA model. These data were confirmed in an additional T cell dependent model, the EAE model. HDAC1cKO mice were completely protected against the development of EAE. The total number of cells isolated from the CNS, consisting predominately of CD4+ T cells, was significantly reduced in the absence of HDAC1. Molecular analysis of HDAC1cKO CD4+ T cells revealed diminished expression of CCR6 in activated HDAC1cKO CD4+ T cells, which is an essential chemokine receptor for the development of arthritis and EAE. This was accompanied with an increased production of IFNγ which was associated with an enhancement of STAT1 phosphorylation in activated HDAC1cKO CD4+ T cells in comparison to WT cells. In line with this finding we observed sections. Relative expression levels of osteoclast, osteoblast and chondrocyte-related genes were determined by real-time qPCR. Results: Longitudinal PET-CT scans revealed a significant decrease in [18F]FDG SUVs in various joints including knees, ankles and shoulders supposing complete resolution of inflammatory processes after TNF blockade. In contrast, [18F]Fluoride was significantly reduced in ankles indicating resolution of local eroded bone surfaces accompanied by normalized osteoblast activity but increased in knees indicating increased systemic bone turnover at sites of active growth plate after therapy. Of note, comparison of repeated in vivoCT images demonstrated a reversal of pre-existing bone destructions indicated by significantly reduced radiographic damage scores upon TNF blockade. Subsequent histological analysis supported complete resolution of synovial inflammation as well as bone healing phenomena indicated by cartilaginous refillings and hyperproliferation of chondrocytes at sites of former bone erosions. Therapeutic intervention led to a reduction of mRNAs encoding genes for tissue-degrading enzymes and osteoclast activity accompanied by increased SOX9 and collagen type II expression, which supports regenerative potential of lesions.
Conclusion:
In vivo small animal multimodal PET/CT imaging provides an objective, non-invasive imaging tool for monitoring and quantifying reversibility of ongoing inflammatory processes and regeneration of existing bone erosions during therapeutic intervention in experimental arthritis. 4 , Ertl, P. 5 , Kiener, H. P. sclerosis. This implies that the effects of Rituximab reach beyond B cells and might influence different leukocyte subsets. In this study we aimed to demonstrate the impact of Rituximab on the frequency and function of leukocyte subsets in RA patients. Methods: Nine patients with active RA were treated with Rituximab. Peripheral blood mononuclear cells (PBMCs) were analyzed at baseline, two weeks and twelve weeks after Rituximab treatment. Lymphocyte subsets were analyzed by flow cytometry. In parallel in vitro suppression assays were performed and measured by 3H-thymidine incorporation. Disease activity was assessed using the Clinical Disease Activity Index (CDAI). Results: We observed that the frequency of leukocyte subsets was not impaired under Rituximab treatment. In addition we could show that the activation status of T cells was not affected by Rituxmab treatment. FoxP3+ CD25+Treg were decreased in numbers and displayed a downregulation of markers associated with activation and function of regulatory T cells. In addition we observed significantly diminished suppressive capacity of Treg in RA patients under Rituximab treatment.
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Microfluidic-based 3D synovial organoid culture reveals mechanisms of synovial tissue formation and inflammatory remodeling
Conclusion:
In this study we could demonstrate an unexpected role of B cell depletion on the frequency, the expression of activation markers and the function of regulatory T cells in patients with RA. Objective: Chronic joint inflammation leading to bone and cartilage damage are the major cause for functional impairment in patients with Rheumatoid Arthritis (RA). Whereas resolution of synovitis and blockade of progressive joint damage can be successfully managed by disease modifying anti-rheumatic therapies, the initiation of bone repair upon therapeutic interventions has only been rarely reported. The aim of this study was to use the in vivo multimodal positron emission tomography/computed tomography (PET-CT) imaging in small animals for monitoring reversibility of systemic inflammatory and destructive bone remodeling processes as well as potential repair of colocalized structural bone destruction during TNF blockade in human tumor necrosis factor transgenic (hTNFtg) mice, an established mouse model of chronic inflammatory, erosive polyarthritis. Methods: 8 week-old hTNFtg mice were treated with anti-TNF antibodies (Infliximab, i. p., 3x times per week, 10 mg/kg body weight) for 4 weeks. Before and after the treatment period isofluran-anesthetized mice received [18F]FDG (fluoro-D-glucose, tracer for inflammation) or [18F]fluoride (bone tracer) (~25 MBq) static PET scans (45 min post injection) followed by whole-body and high resolution leg CT scans (800 kV, 500 µA, 800 ms, 360 projections) using an Inveon PET/CT/SPECT multimodality system (Siemens Medical Solutions). PET reconstructions were conducted with OSEM3D/MAP, FBP algorithm. Standard uptake values (SUV) were calculated using PMOD software. Radiographic damage score was evaluated in 3D reconstructed in vivo CTs using Inveon Research Workplace software and ex vivo high-resolution µCT imaging (Scanco µCT35 Aim: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the IgM (RF) or IgG (ACPA) isotype. The added diagnostic and prognostic value of IgA autoantibodies is being debated. It was therefore the objective of this study to (1) determine the prevalence of IgA-RF and IgA-ACPA in patients with RA and (2) to investigate their potential predictive value regarding response to treatment with methotrexate (MTX) and TNF inhibitors. Methods: To determine the diagnostic sensitivity and specificity sera from 255 RA patients, 258 disease controls and 100 healthy subjects were tested for the presence of IgA-RF and IgA-ACPA by EliA (Thermo Fisher Scientific). IgM-RF and IgG-ACPA were routinely measured by nephelometry and the anti-CCP EliA, respectively. Therapeutic responses defined by simplified disease activity score (SDAI) and American College of Rheumatology (ACR) responses to MTX (n = 94) and TNF inhibitors (n = 105) were analysed. Results: Diagnostic specificity was 95% for IgA-RF and 98% for IgA-ACPA, respectively. Among the 255 RA patients, 49% had at least one type of IgA antibody: 45% were IgA-RF positive (as compared to 61% IgM-RF positivity) and 31% were IgA-ACPA positive (as compared to 56% IgG-ACPA positivity). Importantly, 10.5% of IgA-RF positive patients (i. e. 5% of the total cohort) were negative for IgM-RF (and half of also them for IgG-ACPA) while-apart from two exceptions-all IgA-ACPA positive patients had also IgG-ACPA. Thus, the added diagnostic value of IgA-RF was approximately 5% whereas IgA-ACPA only marginally increased the sensitivity of ACPA testing. Remarkably, the percentage of patients showing a SDAI50 response to TNFi was significantly lower in patients positive for IgA-RF and/or IgA-ACPA (p < 0.0001) compared to IgA negative patients: while 58% of IgA negative (but IgM-RF and/or IgG-ACPA positive) patients showed a SDAI50 response only 25% of the IgA positive ones were responders. Interestingly, IgA-ACPA positive/IgA-RF negative patients were the poorest responders with only one out of nine patients showing a SDAI50 response whereas 4/13 IgA-RF positive/IgA-ACPA negative patients were responders. Seronegative patients also showed a significantly decreased SDAI50 response (p < 0.001) to TNFi compared to IgM-RF/IgG-ACPA positive patients without IgA antibodies. Similar results were obtained when ACR20 was used as primary response criteria. Interestingly, no difference between the various groups was seen with respect to treatment with MTX. Summary/Conclusion: Apart from a moderate added diagnostic value of IgA-RF, IgA subtypes and particularly IgA-ACPA appear to be strongly associated with a diminished therapeutic response to TNF blocking biological drugs, irrespectively of IgM-RF and IgG-ACPA. Therefore their determination may help in further stratification of RA patients and therapeutic decision making. Aim: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the IgM (RF) or IgG (ACPA) isotype. IgA subtypes of both antibodies have been repeatedly reported but their added diagnostic and prognostic value has still not been fully elucidated. It was therefore the objective of this study to (1) determine the prevalence of IgA-RF and IgA-ACPA in patients with RA and (2) to investigate their potential predictive value regarding response to treatment with methotrexate (MTX) and TNF inhibitors. Methods: To determine the diagnostic sensitivity and specificity sera from 287 RA patients, 258 disease controls and 100 healthy subjects were tested for the presence of IgA-RF and IgA-ACPA by EliA (Thermo Fisher Scientific). IgM-RF and IgG-ACPA were routinely measured by nephelometry and the anti-CCP EliA, respectively. Therapeutic responses defined by simplified disease activity score (SDAI) and American College of Rheumatology (ACR) responses to MTX (n = 166) and TNF inhibitors (n = 141) were analysed. Results: Diagnostic specificity was 95% for IgA-RF and 98% for IgA-ACPA, respectively. Among the 287 RA patients, 57% had at least one type of IgA antibody: 50% were IgA-RF positive and 35% were IgA-ACPA positive. 12% of IgA-RF positive patients were negative for IgM-RF and 4.7% of IgA-ACPA positive patients were negative for IgG-ACPA. Importantly, 37% of RA patients were tested negative for RF and ACPA by routine diagnostics (seronegative). In total, 5.2% of seronegative patients had at least one IgA antibody. Remarkably, the percentage of patients showing a SDAI50 response to TNFi was significantly lower in patients positive for IgA-RF and/or IgA-ACPA compared to IgA negative (but IgM-RF and/ or IgG-ACPA positive) patients. Especially IgA-ACPA positive patients did respond poor to treatment with TNF inhibitory drugs. Seronegative patients also showed a significantly decreased SDAI50 response to TNFi compared to IgM-RF/IgG-ACPA positive patients without IgA antibodies. Similar results were obtained when ACR20 was used as primary response criteria. Interestingly, IgA positive patients showed a slightly increased response to treatment with MTX. Summary/Conclusion: Apart from a moderate added diagnostic value of IgA-RF, IgA subtypes and particularly IgA-ACPA appear to be strongly associated with a diminished therapeutic response to TNF blocking biological drugs, irrespectively of IgM-RF and IgG-ACPA. Therefore their determination may help in further stratification of RA patients and therapeutic decision making. subset contributing to the disease pathogenesis of SpA. This study aims to investigate the role of SIRT1 in the pathogenesis of SpA. Methods: Prospective study on 15 patients with aSpA [mean age 42.5 (±12.5), 20% female] and 9 healthy individuals [HC, 39.7 (±11. 3), 55.6%]. Flow cytometry was used to investigate protein levels of SIRT1 in CD28+CD45RA+ naive, CD28+CD45RA-memory and CD28-senescent T-cells. In vitro differentiation of Th17 cells was performed in cell culture experiments in presence of 20 ng/mL IL-6, 10 ng/mL IL-1β, 1 ng/ mL TGFβ-1, 100 ng/mL IL-23, 10 µg/mL anti-IL-4, 10 µg/mL anti-IFNγ and CD3/CD28 Activation Beads (in the ratio beads:cell-number = 1:2) for 11 days. Ex-527 (SIRT1 inhibitor) and Cay10602 (SIRT1 activator) were used to modulate SIRT1 function. IL-17 producing Th17 cells as well as CD25+FoxP3+ regulatory T-cells were measured by flow cytometry. Results: SIRT1 protein levels were higher in naïve T-cells of SpA patients compared to HCs [2.08 (1.17-2.62) vs. 1.49 (1.15-1.9) , p = 0.025]. A comparable increase was also noted in memory [2.11 (1.13-2.66) Hier steht eine Anzeige. Abstracts ml) in the patients with extended and persistent OA, in PARF+ and ERA but not in PARF-, PsA and sJIA. Conclusion: Special groups of JIA showed increased CS activation with elevated levels of MAC in PB in acute phase of disease. The additional decreased capacity in the CP and AP suppose that the complement system as an additional contributor in pathogenesis and/or course of the acute disease. Therefore the testing of COMPL300 in combination with sMAC could be a helpful biomarker for acute JIA disease and furthermore the pharmaceutical blockage of parts of the complement system might be a therapeutical option in therapy resistant patients. tations in the NLRP3 gene on chromosome 1q44, they are perceived as a continuum of one disease entity and labelled cryopyrin-associated periodic syndromes (CAPS). Aim of this preliminary study in a patient with MWS was to find a correlation between the complement system and a disorder of autoinflammation. Method: PBMCs (peripheral blood mononuclear cells) were isolated from blood of a healthy donor and of an individual suffering from MWS by density gradient centrifugation using a Ficoll Paque Premium (GE Healthcare). After washing, PBMCs were incubated with anti-human CD14 Magnetic Beads (BD) to obtain CD14+ monocytes. These were stimulated by addition of cytokines (IL-4 and GM-CSF) for five days to generate immature moDCs (iDCs), which were used for cytokine ELISAs and flow cytometric analyses. IL-6 and IL-1β cytokine ELISAs were performed according to the manufacturer (Biolegend) following stimulation of cells using either LPS or differentially complement opsonized HIV-1. Phenotypical characterization of pathogen-exposed DCs was performed by analyzing characteristic surface markers (CD11c, DC-SIGN, CD86) by multi-color flow cytometry. Results: IL-1β production of iDCs is higher in the patient cells than in the cells of the healthy donor. However, the most significant difference was shown in complement opsonized iDCs. DC-SIGN is higher expressed in complement opsonized iDCs in patient cells compared to cells of a healthy donor (37.12% vs. 28.64%). DC-SIGN is also higher expressed in the iDCs of the MWS patient after stimulation with LPS.
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Conclusion:
The complement system may play an important role in the development of an proinflammatory milieu in patients with disorders of autoinflammation. The phenomenon shown in a patient with MWS has to be reproduced in more MWS patients a well as in patients with other disorder of autoinflammation.
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Complement activation profiles in juvenile idiopathic arthritis
Brunner, J.*, Thomas Giner, Lukas Hackl Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria Background: Juvenile idiopathic arthritis (JIA) summarizes a group of phenotypically heterogeneous chronic inflammatory disease of childhood. The innate immunity is playing a role in the pathogenesis of JIA. Complement is activated by three pathways (classical pathway (CP), lectin pathway (LP) and alternative pathway (AP)). The role of the complement system in the pathogenesis of JIA is still unclear. Methods: Peripheral blood samples (PB) (n = 158) of 57 pediatric JIA patients were analyzed for specific complement pathway activation (COM-PL300 ELISA), complement factor H (CFH)-autoantibodies (CFHAb ELISA) and the soluble MAC (sC5b-9 ELISA) in serum (S) and EDTAplasma (P)-The JIA subgroups were persistent Oligoarthritis (perOA, n = 19), extended Oligoarthritis (extOA, n = 8), rheumatoid factor positive Polyarthritis (PARF+, n = 4) and negative Polyarthritis (PARF-, n = 12) polyarthritis, Enthesitis related arthritis (ERA, n = 4); Psoriatic arthritis (PsA, n = 3) and systemic JIA (sJIA, n = 7). As control group we tested healthy adults (n = 100) and children (n = 18) without inflammatory diseases. JADAS10 Score defined acute phase of disease. Results: JIA patients within acute phase of disease (n = 53) showed lower capacity in CP (82% [38-97% IQR] vs 104% [97-115% IQR] (p < 0.001)) and AP (34% vs 85% [70-99% IQR] (p < 0.001)) compared to the control group in median. This can be concluded to chronic over activation in the two complement pathways even though The: in plasma 3,46 AU/ml and serum 19,55 AU/ml only 40% (29/53) in CP and 36% (26/53) in AP were below the published pathological threshold. Also sMAC was elevated (P 2.3 [1.27-3. 43 IQR] vs 1.2 [0.84-1.84 ] AU/ml) in patients with decreased AP in acute phase (p < 0.009) compared to the control group. No evidence of CFH-autoantibodies was found in our study group. The sMAC levels were significantly (p < 0.009) higher in sera (15.5 [12.03-20.91 IQR] AU/ml) and plasma (1.75 [0.9-3.46 IQR] AU/ml) compared to the control group (S 7.78 [4.9-10.32 Unfortunately, approvals by BASG/EMA-and FDA-authorities are missing for most medications used for ABD-treatment even if according to EULAR-guidelines. Conclusions: In this Middle-European ABD-cohort clinical presentations between patients of Austrian and Turkish origin do not strongly vary, whereas Turkish patients from the non-endemic Innsbruck cohort present differently compared to patients living in Turkey. 93.7% of medical interventions were considered at least as equal to the recommendations, even if including those before publication of the EULAR guidelines. EU-LAR-recommendations not necessarily adhere to authorities' approvals. In the future, the role of such cohort analyses will increase, both from the epidemiological as well as the management and quality of care perspective. 
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Aim:
It is an ongoing matter of research, whether the course of rheumatoid arthritis (RA) can be altered by an early intervention, a concept historically referred to as the "window of opportunity". So far, only short-term disease activity outcomes have been investigated, which are, however, inherently affected by the unknown rate of underlying rate of self-limiting disease. It is unclear, whether the disease course is really affected by the timing of initial treatment. In the present study, we explored whether a long-term adverse course of RA, so called treatment refractory disease, is more likely in patients with longer delays to initial treatment. Methods: Patients were identified from a clinical database at the Medical University of Vienna. We used stringent criteria to define refractory RA ("reRA"): ≥3 treatment courses (≥1 biological) over ≥18 months since diagnosis without reaching low disease activity (LDA) or remission (REM) defined by a Clinical Disease Activity Index (CDAI, ≥10). In contrast, we defined treatment amenable RA ("taRA") as patients reaching LDA, or REM within the first 2 treatment courses. We first matched patients with reRA and taRA 1:1 for time of inclusion in our database to avoid bias by secular trends in management over time. Using the reRA or taRA status as the dependent variable, we performed logistic regression analysis. Furthermore, we performed the same analyses in an unselected group of "all-comers" at baseline regarding their probability of developing reRA. Results: We identified 412 patients who had their last clinic visit at or after July 1 st , 2016: 70 reRA and 102 taRA patients were identified; 240 patients fulfilled neither definition. In the reRA group, female gender was more frequent, age of disease onset lower, and CDAI higher at first presentation. Remarkably, the time to first DMARD treatment was significantly delayed between reRA and taRA (. Fig. 1 ).
In the matched multivariate model, treatment delay (p = 0.047), female gender (p = 0.038) and higher disease activity (p < 0.001) were significant. In the logistic regression analysis of the 412 patients, treatment delay was significant univariately (p < 0.001) and after adjustment for other significant predictors (p = 0.007). We then conducted a matrix model based on this analysis with predicted probabilities of developing reRA. Summary/Conclusion: Our data suggest that delay to initial treatment affects the long-term course of RA. Earlier treatment initiation thus may change the severity of RA.
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Clinical presentation and treatment of Adamantiades-Behçet's disease in Middle-Europe: A retrospective cohort study Objectives: To assess epidemiological data in a Middle-European cohort of ABD-patients, together with the adherence of their medication with international guidelines. Methods: In a retrospective cohort study, data from an Austrian university hospital center were analyzed independent from the medical discipline involved. After ethical approval screening for ABD-patients in the clinical information system resulted in 1821 documents from 1997 to 2016. Patients fulfilling the ICBD criteria were included, and ABD-symptoms and -signs together with medical interventions for immunosuppression, anticoagulation and pain management were identified by individual chart reviews and evaluated for conformity with international recommendations. Results: A total of 76 ABD-patients were identified with 39.1% Austrian and 37.0% Turkish origin, and an average male-to-female ratio of 0.86 (0.39 in patients with Austrian and 1.43 with Turkish background) and 3.3 in patients with venous manifestations. Out of 174 medical interventions, 55.2% fully matched the EULAR-recommendations and 93.7% were considered at least as equal to the recommendations. Indications for TNF-inhibition were in line with the recommendations by Sfikakis P et al.
Abstracts
DI improvement ≥0.22. Maintenance of response was evaluated as proportion of pts who had responded to bari at entry into LTE and maintained response at wk 96. Data are also provided for pts who had not responded to bari at entry into LTE who achieved response.
Results: Approximately half the pts in the durability analyses were categorised as LDA by wk 24 and the proportion of pts in the LDA category were similar or higher at wk 96. Three quarters of pts across groups demonstrated HAQ-DI improvement by wk 12 and more than half achieved MCID at wk 96. Most responders at entry into LTE maintained their response through wk 96. More than 25% of SDAI and HAQ-DI nonresponders at entry into LTE achieved response after 96 wks of treatment. Aim: Temporary interruption of RA therapy is common in clinical practice; therefore, rapid clearance and low immunogenicity may be useful DMARD attributes. Baricitinib (bari) is a non-biologic Janus kinase (JAK)1/JAK2 selective inhibitor with a pharmacokinetic half-life in RA patients of approximately 13. It has demonstrated improved clinical efficacy compared to MTX, adalimumab and placebo (pbo) with a satisfactory safety profile when administered once daily to RA patients in 4 completed Phase 3 studies. These analyses aimed to characterize temporary interruptions of study drug during these studies and explore the kinetics of RA symptoms during and following interruption. Methods: During bari Phase 3 studies, investigators were required to document temporary interruptions of study drug, including timing, reason and duration, using electronic case report forms. In 2 studies, patients recorded RA symptoms (duration and severity of morning joint stiffness, worst tiredness and worst joint pain) daily for 12 weeks. Post hoc analyses investigated changes in these scores among patients randomized at least 7 days prior to interruption, having an interruption that lasted at least 3 days, and retreated. Results: Across the 3 pbo-controlled studies, interruptions occurred in a larger proportion of patients with bari than pbo only in the biologic DMARD-inadequate responder (IR) study RA-BEACON. In the 2 active comparator-controlled studies, the lowest rates of interruption were in the bari monotherapy arm of the DMARD-naive MTX-controlled RA-BEGIN study, and proportions were similar for bari and adalimumab in the MTX-IR study, RA-BEAM. Adverse events (predominantly non-serious, mild or moderate infections, most commonly of the respiratory tract) were the most frequent reason for interruption. Few patients interrupted for the reason of abnormal laboratory results. Most interruptions lasted for 2 weeks or less; in RA-BEAM, interruptions appeared shorter in duration for bari than for adalimumab. Diary measures indicated modest symptom increases during interruption compared to the last pre-interruption value, with a return to pre-interruption values or better after resumption of study drug. Conclusions: Consistent with its pharmacologic properties, brief temporary interruptions of bari during Phase 3 studies were associated with minor increases in RA symptoms, which resolved following resumption of therapy. A small molecule with a short half-life may offer advantages over injectable biologic therapies with respect to drug interruption for clinical cause in RA patients. To assess the safety of bari in pts with active RA across 8 completed studies (4 phase 3, 3 phase 2, 1 phase 1b) and 1 ongoing long-term extension study). Methods: Primary safety analysis was based on 6 studies (all with bari 4-mg once daily [QD] and placebo [PBO] arms) and dose response assessments on 4 studies (all with bari 2-and 4-mg QD and PBO arms). In addition, the "all-bari" RA set included all pts exposed to any bari dose. Two studies contained active comparators. Results: In total, 3464 pts were exposed to bari (4214 patient-years [PY]; 2166 pts [62.5%] >1 year; 467 [13.5%] >2 years). In controlled periods of the program, no increases in deaths, adverse events leading to study drug discontinuation, malignancies, major adverse cardiac events, or serious infections were seen for bari versus PBO/active treatment. Herpes zoster was reported more frequently for bari vs PBO. In randomised, controlled periods of the program, tuberculosis (TB) was reported in 2 pts: 1 bari 4 mg, 1 adalimumab; in uncontrolled periods, 6 TB events were reported (bari 4 mg: 2 with incomplete TB screening, 3 without organism confirmed). All TB occurred in endemic areas. Two gastrointestinal perforations were reported (0.05/100 PY). Bari treatment has been associated with changes in selected hematology/clinical chemistry analytes; few pts (<1%) discontinued due to abnormal laboratory results. There was no increased risk over time for the above outcome measures with prolonged exposure. Aim: Baricitinib (bari) demonstrated clinical efficacy in Ph3 trials in RA patients (pts) naïve to DMARDs (RA-BEGIN1); and in RA pts with inadequate response to conventional synthetic DMARDs (RA-BEAM2 and RA-BUILD3) or biologic DMARDs (RA-BEACON4). The objective was to evaluate durability and maintenance of efficacy over an additional 96 weeks (wks) of bari treatment. Methods: Pts included were those randomised to bari in an originating study (OS), completed that study without rescue (52 wks in RA-BEGIN or RA-BEAM; 24 wks in RA-BUILD or RA-BEACON), and entered the long-term extension (LTE) study ≥96 wks prior to data cut-off. Durability of response was evaluated as pts achieving low disease activity (LDA) of SDAI ≤11 and minimal clinically important difference (MCID) of HAQ-swollen joint is predicting subsequent joint damage. Since joint assessment is regarded time-consuming, a tension exists between comprehensiveness, e. g. using complete joint counts (JC; 76/78 or 66/68), and feasibility. Reduced JC, such as the 28 joint count, however, may be less valuable in PSA than RA due to differences in joint patterns. Here, we examined the validity of a reduced 28 swollen and tender JC, using the extended JC as comparators. Methods: We analyzed data from a random subset of 80% of patients enrolled in the ADEPT (n = 264) and the IMPACT-2 trial (n = 163). In ADEPT a 76/78 JC was performed, in IMPACT-2, it was the 66/68 JC only. At week 24 of the two trials, patients with a complete absence of SJC or TJC by the 28-count were analyzed for their residual joint activity. Sensitivity and NPV for each joint count were calculated for each study. Finally, we analyzed the residual tender and swollen joints of 76/78 and 66/68 JC remained active in patients with a 28-joint count of 0 at endpoint. [1] . When evaluated by country, abatacept retention rates have shown some variation [1, 2] . To provide a local perspective, we compared 2-year retention rates and clinical outcomes by treatment line in the Austrian cohort of patients enrolled in ACTION. Methods: ACTION was a 2-year, prospective, observational, international study of patients (≥18 years) with moderate-to-severe RA who initiated IV abatacept as first-or second-/further-line biologic therapy in routine clinical practice. Biologic-naïve and -experienced patients were enrolled between May 2008 and December 2013. Baseline demographics and disease characteristics were recorded. Crude abatacept retention rates were estimated by Kaplan-Meier analysis, and clinical outcomes (EULAR reResults: Investigation of SJC at week 24 in ADEPT showed that 63 of all 264 patients (23.9%) achieved a SJC28 = 0; of these 63 patients, 51 (81%) also had a SJC66 = 0 and 50 (79.4%) had a SJC76 = 0. Twelve and 13 patients, respectively, had residual SJC76 or SJC66 while having a SJC28 = 0. Of the 52 patients with a TJC28 = 0, 41 and 39, respectively, had also TJC78 = 0 and TJC68 = 0, while 11 and 13 patients had residual TJC68 or TJC78. In IMPACT2, 50 of 163 patients (30.7%) achieved SJC28 remission, with 15 patients (30%) of these remaining active by SJC66. TJC28 remission was achieved by 44 patients, with 17 patients (38.6%) not achieving complete TJC68 remission. Exploration of individual residual swollen and tender joints showed mainly foot and ankle joints being active/tender at week 24. Conclusion: Absence of swelling by the 28 joint count in PsA seems to not adequately reflect the situation of all relevant joints, as in at least one of four patients residual clinical activity is detectable by more comprehensive 76/78 and 66/68 joint counts. Assessment of ankle and foot joints, especially MTPs, contributed numerically most to the missed joints. These limitations should be considered when treating PsA patients to target. Fig. 1 . The overall crude abatacept retention rate (95% CI) at 2 years was 60.5% (49.4, 69.8; . Fig. 2) . At 2 years, retention rates (95% CI) in biologic-naïve and -experienced patients were 65.1% (45.7, 79.0) and 58.0% (44.1, 69.6), respectively (. Fig. 2) . The most common reasons for discontinuation among biologic-naïve and -experienced patients, respectively, included inefficacy (3/11 [27.3%] and 15/25 [60.0%]) and safety (1/11 [9.1%] and 1/25 [4.0%]). At 2 years, 81.3% and 88.9% of biologic-naïve and -experienced patients, respectively, had achieved CDAI low disease activity or remission. Good/moderate EULAR response rates (95% CI) at 2 years were 85.7% (67.1, 100) in biologic-naïve and 100% (100, 100) in biologic-experienced patients. Conclusions: In this cohort of Austrian patients with RA treated in a real-world setting, the overall IV abatacept retention was >60% at 2 years and similar to that in the overall ACTION study (54.4%) [1] . Retention rates were higher in patients receiving earlier treatment lines. In contrast to the overall ACTION study, clinical outcomes at 2 years in this Austrian cohort were better in biologic-experienced than biologic-naïve patients.
Conclusions
RABBIT risk score and ICU admission due to infection in patients with rheumatoid arthritis
Abstracts
presence of AAPA may be useful for prediction of Tumor-Necrosis-Factor-inhibitor (TNFi) treatment response. Methods: RA patients starting their first TNFi treatment were identified and tested for AAPA (by ELISA using two acetylated peptides derived from vimentin), RF (by nephelometry), and ACPA (by ELISA) at baseline. Based on logistic regression analysis, Odds Ratios (OR) including 95% confidence intervals (95% CI) for association with a 50% response of the Simplified disease activity index (SDAI50) and for reaching SDAI low disease activity (LDA) or remission at 6 months were calculated. We also performed longitudinal analysis by General Estimated Equation analyses (GEE) and Cox-regression. Results: Among the 93 patients starting on a TNFi (85% female, mean disease duration: 7.7 ± 7 years; mean SDAI: 20 ± 13), 53% were positive for AAPA, 57% for ACPA and 61% for RF; 35.5% were triple positive, and 7.5% only for AAPA. There was a higher proportion of RF+ and ACPA+ patients in the AAPA+ group. Presence of AAPA was associated with significantly higher rates of SDAI50 response (44% vs. 18%; OR 3.58 95%CI: 1. Aim: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/anti-citrullinated protein antibodies (ACPA) negative patients. Here we investigated whether the Fig. 1 9 Hierarchical multiple regression analysis modeling the associations of grip strength, musculus quadriceps femoris strength and lower extremity function (SPPB) with workability in 100 patients with rheumatoid arthritis spearman's correlation coefficient was calculated for association between the different parameters. Group differences were compared by using the t-test for independent variables or Kruskal-Wallis test. Results: Clinical and patient-reported data of 101 patients were available. 93.1% of patients were female. Patients had been suffering about 60 months from symptoms prior to final diagnosis of PSS. The mean disease duration was 4.9 years (±4.4 (SD)) in this cohort. The comparison of four different age groups revealed a statistically significant difference between the age groups ≤50 years and ≥ 70 years of age. Within these groups the IgG value (18.18 vs. 12.7 (mean)), and a Sicca Score (21.3 vs 44.9) demonstrated a statistically significant difference (p < 0.05). We found a negative correlation of IgG with age (r = −0.345, p < 0.01) and the PROFAD score (r = −0.233, p < 0.01). Patients who were positive for ANA, RO, LA and RF had a lower disease burden as measured by ESSPRI (3.4 vs. 5.0) and a higher IgG (18.3 vs 12.5) compared to patients with a negative RF. Summary/Conclusion: We characterized a large Austrian PSS cohort. Our results suggest that IgG values normalize with age while the extent of sicca symptoms increases with age. Data of a longitudinal study will be needed for better description of the natural course of the disease.
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Work ability in patients with rheumatoid arthritis: A cross sectional study on the role of muscle strength and lower extremity function Aims: Rheumatoid arthritis (RA) is a chronic disabling disease that can lead to work disability. Work ability in RA appears to be multifactorial and the role of muscle strength and lower extremity function has not been studied yet. Aim of this study was to assess levels of work ability in an outpatient population with seropositive rheumatoid arthritis, and to explore the association between muscle strength, lower extremity function and work ability, at given socio-demographic and clinical conditions. Methods: We conducted a cross-sectional study at a Viennese rheumatologic outpatient clinic. For 100 seropositive RA patients between 18 and 65 years (working age), work ability was determined with a single item of the Work Ability Index, the Work Ability Score (WAS). The WAS measures current work ability compared to lifetime best and is scored on a 0-10 response scale. Handgrip strength and femoral muscle strength were measured with a dynamometer and lower extremity function with the Short Physical Performance Battery (SPPB). Pain intensity was obtained with a visual analogue scale and disease activity with the Clinical Disease Activity Index (CDAI). Linear multiple regression analyses, stepwise adjusted for sociodemographic and clinical factors were used to assess associations of muscle strength and lower extremity function with work ability. Results: Mean age of participants was 50.5 years and two thirds were female. The majority was living in a relationship and had at least secondary school education. Median disease duration was 6 years, median disease activity was low (CDAI = 8 points) and mean pain intensity was 3.6 points on a VAS scale of 1-10 points. More than half of the participants suffered from at least one comorbidity and took at least one additional medication (other than RA). 59% of participants were employed at time of inclusion and reported a good work ability (WAS median = 8; IQR = 6.25-9) as compared to those without employment reporting poor workability (WAS median = 4; IQR = 2.5−7). . Centre for Medical Genetics, Hanusch Hospital, Vienna, Austria Objective: Despite the high frequency of HFE gene mutations in Western Europe, widespread screening for hereditary hemochromatosis is not recommended due to its variable phenotype. A premature osteoarthritis-like disease including the hip joints is the most frequent manifestation of hereditary hemochromatosis. Therefore, screening of patients with severe osteoarthritis of the hip could identify patients with hereditary hemochromatosis. Methods: In this prospective cross-sectional study, 940 patients aged <70 years with end-stage osteoarthritis of the hip undergoing elective joint replacement surgery were screened for hereditary hemochromatosis and compared to age-and sex-matched controls. Results: No increase in prevalence of the homozygous C282Y mutation or ferritin and transferrin saturation levels was found in the study cohort with severe osteoarthritis of the hip compared to controls from the general population. Conclusion: Our screening approach could not identify an increased prevalence of HFE gene mutations and iron overload in younger patients with severe osteoarthritis of the hip. Aim: The aim of this study was to characterize our cohort of patients with primary Sjögren's Syndrome (PSS) for a better understanding of patients and course of disease. Methods: In this observational study PSS patients fulfilling the American-European consensus classification criteria from the outpatient clinic of the Medical University Graz were characterized by routinely assessed parameters like disease duration, ESSDAI (EULAR Sjögren's Syndrome disease activity index), ESSPRI (EULAR Sjögren's Syndrome Patient Reported Index), PROFAD (Profile of Fatigue and Discomfort), sicca score (mean of 10 VAS scales about dryness-symptoms), IgG (Immunglobulin G), ANA (Antinuclear-Autoantibody) and RF (Rheumatoid factor). The Abstracts tron emission tomography (PET/CT) have been increasingly used in primary large vessel vasculitis (LVV) including giant cell arteritis (GCA) and Takayasu arteritis (TAK). However, there is still significant controversy and uncertainty about when to use which imaging technique, and whether imaging might be helpful during follow-up to assess disease activity and damage. We aimed to develop EULAR recommendations for the use of imaging modalities in LVV in clinical practice. Methods: The EULAR Standardised Operating Procedures have been followed. A systematic literature review was conducted to retrieve data on the role of imaging in LVV. Based on evidence and expert opinion, the task force consisting of 20 experts (physicians, a health care professional and patients) from 12 EULAR countries developed recommendations, with consensus obtained through informal voting. The final level of agreement was voted anonymously. Results: A total of 12 recommendations have been formulated. The task force recommends an early imaging test in patients with suspected LVV, assuming high expertise and prompt availability of the imaging technique. Ultrasound has been suggested as the first choice imaging modality in GCA, because of a good performance of the test, easy access, absence of radiation and other procedural risks, and low resource use. MRI, and in case of predominant large vessel (LV)-GCA, PET and CT, might be alternatives to ultrasound. For TAK, MRI is the preferred imaging modality, because of the absence of radiation exposure and the possibility to assess simultaneously the vessel wall and luminal changes of the aorta and its proximal branches. PET, CT and ultrasound can be used as alternatives. In patients with a suspected flare of LVV, imaging might be helpful to assess disease activity. The frequency and choice of imaging modalities for long-term monitoring of structural damage remains an individual based decision. All imaging should be performed by a trained specialist using appropriate equipment, operational procedures and settings. Summary/Conclusion: These are the first EULAR recommendations providing up-to-date guidance on the role of imaging in the diagnosis and monitoring of patients with (suspected) LVV.
Characterization of patients with primary Sjögren's Syndrome
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Evoked potential amplitudes during emotional face processing in patients with fibromyalgia syndrome lower extremity function (SPPB) with work ability. The total variance of work ability explained by the fully adjusted model was 39.9% for hand grip strength, 44.6% for M. quadriceps femoris strength and 48.9% for the SPPB score. All three parameters remained significantly associated with work ability after adjusting for socio-demographic and clinical variables. In the fully adjusted model for hand grip strength and M. quadriceps femoris strength also female sex and a pain intensity and in the fully adjusted model for lower extremity function (SPPB) also pain intensity and disease activity (CDAI) were significantly associated with work ability. Conclusion: Workability, hand grip strength and M. quadriceps femoris strength are lower in RA patients than in the general population of that age. Hand grip strength, M. quadriceps femoris strength and lower extremity function (SPPB) were significantly associated with work ability, also after adjustment to sociodemographic and clinical characteristics. Work disability occurs early in RA. Staying at work despite this chronic disease must be an important therapeutic and rehabilitative goal for physicians and healthcare coverage. We identified potentially modifiable factors to improve work ability in RA. Our results indicate that work ability may be improved by increasing lower extremity function and muscle strength additionally to efforts to reduce pain intensity and disease activity. 
Aim:
Fibromyalgia syndrome (FMS) is a chronic condition of widespread pain accompanied by symptoms such as depression, fatigue and sleep disturbance. In addition to central nociceptive sensitization, emotional dysregulation may play a role in FMS pathogenesis. This is indicated, for example, by altered reactivity to affective stimuli, selective processing of negative information, and deficits in affective communication and emotion-based decision-making. This study explored the central nervous processing of facially expressed emotions in FMS. Methods: Event-related potentials (ERPs) of the EEG were recorded in 40 FMS patients and 45 pain-free controls during exposure to 160 images of faces, which had to be classified according to their emotional content (fear, anger, disgust, or sadness). Results: While patients exhibited an overall weaker early positive potential shift (70-250 ms) than controls and stronger negative ERP components (30-340 ms), no group differences were found for later potential components, i. e. the P300 or late positive slow wave. Patients rated the emotional faces as more arousing than did the controls; classification performance did not differ between groups. Summary/Conclusion: ERP results indicate that differences between FMS patients and controls were restricted to early processing stages. The stronger negative components in patients may be connected to stronger early allocation of attention towards emotional faces, greater effort during decoding of facial expressions and evaluative affect-recognition. Weaker positive potentials may be related to reduced visuo-spatial orienting or reflect a mechanism of avoidance and early attentional disengagement. The lack of group difference for later potentials suggests that patients did not differ from controls in the magnitude of the central nervous affective response related to affect evaluation and perceived emotional arousal. Results concerning task performance and subjective ratings suggest no deficits in recognition performance but elevated intensity of emotional experience in FMS patients. 3, 30; 2, 51; 2, 58; 2, 52; 2, 49, 2; 2, 4; 2, 2; 2.0; 2, 60; 2, 61; 2, 45; 2, 63; 2, 20 . Medianwerte von Entzündungszeichen in den Laborwerten (BSG in mm/1. Stunde und CRP in mg/l) waren immer im Normalbereich (BSG und CRP bei RA 15; 12; 12; 12, 5; 14 und 2, 0; 2, 0; 2, 0; 2, 0; 2, 0; bei SpA: 8; 6; 7; 8; 8; und 2,0; 1,4; 1,4; 1,1; 1,0 bei PsA 9; 8; 9; 7 (V7); 6 (V8); und 1,6; 1,5; 1,4; 1,9 (V7); 0,8 (V8) Ergebnisse: Bei 73 % der Pat. konnte der GZ-Index verbessert werden, 22 % der Pat. zeigten keine Veränderung und 5 % verschlechterten sich. Die durchschnittliche Verbesserung im GZ-Index betrug 14 ± 13 Perzentilpunkte (n = 2448, t = 53,70, p = ,000*** [abh. T-Test]). Anatomische Merkmale -wie BMI und Bauchumfang -blieben bei 84 % der Pat. unverändert, die durchschnittliche Gewichtsabnahme betrug 1 kg (mit Modul Diätologie: 3 kg). Der systolische Blutdruck konnte um 4 ± 13 mmHg reduziert werden. Die körperliche Leistungsfähigkeit (Watt am Ergometer bei gleicher Herzfrequenz) erhöhte sich um 10 ± 11 Perzentilpunkte. Die am deutlichsten ausgeprägten Effekte der GVA-Maßnahme zeigten sich in den Beschwerdekennwerten, indem 92 % der Pat. über eine signifikante Verbesserung berichteten (Verbesserung um 31 ± 21 Perzentilpunkte). So konnte die Schmerzangabe in der Visual Analogue Scale (VAS) im Mittel um 2 ± 1,5 Einheiten, von 4,8 auf 2,8, gesenkt werden. Der subjektive Gesundheitszustand verbesserte sich um 14 ± 13 von 66 auf 80 (jeweils p < ,000*** [abh. T-Tests]). 35 % der GVA-PatientInnen rauchten bei Aufnahme, davon nahmen 41 % an einer Raucherberatung teil. 10,5 % der RaucherInnen waren bei Entlassung abstinent, den verbleibenden RaucherInnen gelang eine Reduktion des Zigarettenkonsums (-4,7 ± 6,4 Aim: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systemic outcome data regarding patient-reported outcomes and health economic parameters reflecting the real world use of golimumab in Austria are currently available. Methods: GO-ACTIVE is a prospective non-interventional, multi-center study in Austria. The impact of golimumab therapy on work productivity and Activity (WPAI) and quality of life (RAQoL for RA patients, AsQoL for axSpA patients, PsAQoL for PsA patients, NAPPA for PsA patients with nail involvement) is assessed by using patient reported outcomes. CDAI (for RA and PsA patients) and BASDAI (for axSpA patients) are used to explore disease Activity. Furthermore, relevant parameters concerning treatment patterns, safety, and healthcare resource utilization during routine golimumab treatment are assessed. Patients (target recruitment: n = 320) will be followed for up to 2 years. Objective: A multidisciplinary therapy program during an inpatient rehabilitation stay is applied to improve the impaired function and the pain to realize long lasting effects on patients' health. The aim of this study was to observe in a follow up trial the sustainability of a shoulder rehabilitation in the rehabilitation centers of the PVA in Austria. Design: In a multicenter study the impact on pain, sleep quality and shoulder function, respectively biomarkers for stress and pain during threeweek inpatient rehabilitation was investigated. 4 rehabilitation Centers of the PVA, participated in this study: SKA Bad Aussee, SKA Bad Ischl, SKA Gröbming, SKA Saalfelden. Patients: 150 inpatient rehabilitation patients (age 30-75 years) with painful shoulder disorders were recruited to a follow up study (baseline, three weeks, three months, six months). Methods: Data was gathered by standardized questionnaires concerning function and sleep quality, pain intensity was determined by visual analogue scale (VAS). Biomarkers for stress, pain and inflammation (CRP, Serotonin, ACTH, Dynorphin, β-Endorphin) were analyzed by ELISA technique or HPLC. Results: Many investigated parameters, mainly pain (VAS) and function (Quick Dash/Constant Murley score) improved significantly during and after the rehabilitation program. Only relatively little effects could be seen in the biomarkers in serum. No difference in pain reduction between men and women was found.
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Autoantikörpertestung aus der Sicht von klinisch tätigen Ärzten
Conclusion:
The improvement in pain and function of shoulder patients demonstrates that an inpatient multidisciplinary rehabilitation program is effective with a good outcome and long lasting effects on shoulder complaints. 
Aktueller Stellenwert der stationären Rehabilitation im Management von PatientInnen mit rheumatoider Arthritis
